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Abstract The diversity of nanotechnologies and of
the governance challenges that their applications raise
calls for exploration and learning across different
cases. We present an Upstream Oversight Assessment
(UOA) of expected benefits and potential harms of
nanoparticles made of a synthetic polymer (PLGA) to
improve vaccines for farmed salmon. Suggested by
Jennifer Kuzma and colleagues, an UOA may help
identify and prioritise research needs, and it may
support evaluations of the adequacy of relevant
existing regulatory frameworks. In this work, the
UOA approach is modified and supported with
elements from the uncertainty analysis framework
developed by Warren Walker and colleagues. Empir-
ically, we draw on relevant available published
literature and insights generated in an ongoing nano-
particle salmon vaccine project, in which one of the
authors participates. Nanotechnologies have not pre-
viously been encountered in the regulatory context of
fish vaccines, which in part raises unique challenges
due to prospective large scale vaccine use in semi-
open aquatic systems. Strengthened through cooper-
ation between ELSA and technology researchers we
found the UOA useful for an early mapping of
benefits and concerns, and for identifying areas in
need of further research prior to a nanoparticle based
salmon vaccine is developed and taken into use. We
consider our approach to represent one among several
complementing initiatives that seek to contribute to
early stage evaluations of possible negative side
effects, broadly conceived, in order to facilitate a
more robust nanotechnology development.
Keywords Nanotechnology.PLGA.Upstream
oversightassessment.Vaccines.Salmon.
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Facilitating Anticipatory Governance
of Nanotechnologies
A primary scientific rationale for delineating nano as
a new field is that objects can express novel properties
at the nanoscale. Although the limits of the nanoscale
remain disputed, the weight given to this scale in
definitions of ‘nanoscience’ and ‘nanotechnology’
allows the latter terms to refer to a highly diverse
range of disciplines, activities and objects. Discus-
sions about risk governance of nanotechnologies
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particles made of different metal oxides and nano-
silver. If these examples are prominent in risk oriented
nanotechnology discourses, it is not without reason.
The mentioned examples are important because they
are either already used on a rather large scale in a
range of products or are expected to be so in the near
future. Further, toxic effects have been identified for
such nanomaterials in different animal model systems,
and/or they have been found to involve environmental
hazards.
Nanotechnology has been taken to offer an arena
for experimenting with ways to include societal,
ethical and environmental concerns in early stages
of innovation processes in order to promote a more
robust technology development [52]. This includes
efforts to foresee social and environmental implica-
tions of emerging technologies, to engage wider
publics in innovation processes, and to enhance the
sensitivity and reflexivity of technology developers to
social and environmental concerns. These efforts may
be collected under the broad term ‘anticipatory
governance’ [7, 37]. The scope of this work, however,
is more limited, as we here focus on addressing
benefits, harms and uncertainties of a specific
nanotechnology application.
Emphasising the diversity of nanomaterials and the
diversity of the particular challenges that may
associate their use in different contexts, we explore
prospects and concerns of a project in immunobioen-
gineering that investigates the potential of polymeric
micro- and nanoparticles to enhance vaccine formu-
lations for farmed salmon. Drawing on previous
experiences with the use of polymer PLGAs (poly-
lactide-co-glycolic acids) in targeted drug delivery in
other contexts, the objective of this research is to
develop efficacious vaccines against intracellular
pathogens, which are not easily addressed by way of
standard vaccines. A successful vaccine of this kind
would have significant positive influence on animal
welfare and the economics of salmon farming. This is
an application of nanotechnology that to our knowl-
edge has not been addressed earlier in nanotechnol-
ogy governance discourses.
We examine this case by way of a modified
Upstream Oversight Assessment (UOA). Developed
by Kuzma [43, 44], the aim of this approach is to
contribute to a robust technology development
through identifying knowledge gaps, through indicat-
ing priorities for further research, and through con-
siderations of the adequacy of relevant existing
regulatory frameworks. The UOA may in this way
contribute to that public trust in technologies is
fostered. Although we note that a comprehensive
evaluation of salmon vaccines ultimately should also
take broader questions of the ethical and environmen-
tal sustainability of salmon farming (in its present
form) into account [63], we consider these broader
issues to be outside the scope of this article.
While the PLGA material is considered to be rather
low toxic in itself, the prospect of using it in
nanoparticle vaccines in context of aquaculture raises
a range of unique concerns, for instance relating to
that the vaccine is to be used in a rather different
animal (i.e. fish vs. mammals), and to the use of large
volumes of vaccine particles in semi-open marine
systems (i.e. salmon farms). We find that the approach
taken may help identify issues in need of further
research and regulatory attention prior to a finaliza-
tion and marketing of such nanoparticle based fish
vaccines. As relevant to this case, we offer concrete
suggestions for doing so.
In general, however, we find it unlikely that there will
be resources available for performing an upstream
assessment of this kind for each nanotechnology
research project. Accordingly, we end this article by
endorsing the further development of voluntary meas-
ures and codesofconducts forgood technology research
practise. Along with the approach taken here, these
initiatives may stimulate a more robust nanotechnology
research development in different contexts.
Methodology, Concepts and Materials
We explore the case PLGA nanovaccines for salmon
by way of a modified Upstream Oversight Assess-
ment (UOA). Developed and proposed by Kuzma
[43, 44] the UOA is a case based method, the purpose
of which is to draw attention to areas in need of
further research in order to help prepare for the
governance of these technologies. It focuses on
potential implications of emerging nanotechnologies
including benefits and issues of hazard and exposure
for researchers, workers, consumers and the environ-
ment. It does so through addressing beneficial
properties as well as safety issues of nanomaterials
in the context of their application, and through
58 Nanoethics (2011) 5:57–71identification of strengths and weaknesses of relevant
regulatory and monitoring frameworks.
In practise, the UOA proceeds from posing a series
of research questions, which are answered to the
extent possible through available means. This work
has been guided by the following questions, which we
have adapted from Kuzma et al. [44] with respect to
the present case: What are expected benefits of using
PLGA nanoparticles in salmon vaccines? What are
the identified risks, and what are the uncertainties
with regard to harmful impacts on human health and
the environment? What information would be needed
to further address risks, uncertainties and benefits?
Which regulatory frameworks are involved, and are
there particular regulatory uncertainties in this context?
For the purpose of this work, we have modified the
UOA in two significant ways. First, the UOA as
suggested by Kuzma and colleagues is a comparative
method, which proceeds to develop a relative ranking
of the pertinence of relevant issues in need of further
attention across a range of nanotechnology applica-
tions within a certain area. As our work comprises
only one case study, it does not feature a comparative
aspect. The choice of working with only one case,
however, allows for a more comprehensive analysis.
What we gain in the ‘assessment’ dimension of the
UOA we forgo with respect to ‘oversight’.
Second, we have supported the UOA approach
with elements from the uncertainty analysis frame-
work developed by Walker et al. [74]. This frame-
work has previously been used for analyzing
uncertainties of other emerging technology applica-
tions, including GMO crops [41], gene-silencing [42],
and DNA vaccines in salmon aquaculture [27]. The
framework has also been used to review the state of
knowledge and uncertainty of environmental health
and safety aspects of nanomaterials in general [29]. In
accordance with this framework, we use ‘uncertainty’
as a generic term for the situation of imperfect
knowledge. In this framework, uncertainty is seen to
include three dimensions. First, ‘location’ identifies
where the uncertainty is manifested within a system
model. Second, ‘level’ identifies the degree of
uncertainty, spanning from ‘statistical uncertainty’
over ‘scenario uncertainty’ and ‘recognized igno-
rance’ to ‘complete ignorance’. Third, ‘nature’ con-
cerns the issue of whether uncertainty may be
epistemic (and hence be reducible) or ontic (due to
variability).
Along with Walker et al. [74], we structure our
analysis of uncertainties in terms of their location.
However, while ‘location’ for Walker and colleagues is
determined in relation to a (qualitative or quantitative)
cause-effect model, this is not the case here. In this
work, location refers to a (conceptual) map of the
system in which it is plausible that the nanotechnology
in question may have significant impacts for humans
and the environment. Further, the question of uncer-
tainty levels will only be responded to in terms of
rather generalized characterizations. As the term ‘risk’
is commonly conceptualized quantitatively as the
product of the magnitude of hazard and the likelihood
of exposure, it is here understood as ‘statistical’
uncertainty. We note that as no such relationships have
been quantified for the vaccine examined here, the
term risk does not apply. Accordingly, addressed
uncertainties in this case range between ‘scenario
uncertainty’ and ‘recognized ignorance’.
Empirically, we primarily draw on the available
published literature relevant to PLGA, its use in
nanoparticles, fish vaccinology, and existing fish
vaccine regulations with relevance to the European
Economic Area (EEA) and Norway in particular.
Further, we benefit from insights generated in an
ongoing project that seeks to develop PLGA nano-
particle based salmon vaccines, in which one of the
authors (B.N. Fredriksen) participates.
The Case of PLGA Nanoparticles for Salmon
Vaccines
Polymers have been used in pharmaceutical applica-
tions for several decades. One of the most common
methods for microencapsulation dates back to the late
1980s [62], and is still in use today although with
modified protocols. The following section aims at
introducing the relevance of PLGA polymers for fish
vaccines.
A Need for Efficient Fish Vaccines
Following a shift from farming in ponds to the use of
sea pens in the 1970s, salmon aquaculture has
expanded tremendously. In Norway, salmon aquacul-
ture production has grown from less than 50.000 t in
1987 to a level of close to 1.000.000 t in 2010,
maintaining Norway as the leading exporter of farmed
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growth of the salmon farming industry has been the
development of effective fish vaccines [11, 70].
During the late 1980s and early 1990s the use of
antibiotics reached its peak due to massive outbreaks
of bacterial diseases. Introducing oil-adjuvanted vac-
cines (adjuvants are agents that modify/enhance
effects of other agents) with inactivated bacteria as
antigens drastically reduced the number of outbreaks
and the losses from these diseases became negligible
[20, 22, 54].
In spite of their importance for modern salmon
aquaculture, available oil-based vaccines only provide
sub-optimal protection towards some pathogens,
notably a range of viruses, intracellular bacteria and
macro-parasites [33, 70]. An important example is the
salmon vaccines against a highly infectious viral
disease, infectious pancreatic necrosis virus (IPN),
for which there still are no commercial vaccines
available that confer long lasting immunity [30]. In
2009 there were 223 outbreaks of IPN in Norway
[59]. Moreover, the traditional oil-adjuvanted vac-
cines have been found to have side effects such as
injection site organ adhesions, melanin deposition
and skeletal deformations [11]. Further, incidents
have been reported on systemic autoimmunity in
farmed salmon [39]. While vaccine derived side
effects have been reduced through optimization of
existing adjuvant formulations, a strong motivation
remains for developing new vaccine formulations to
help reduce the spread of viral diseases.
The Role of Carrier Systems in Vaccinology
In later years there has been a general trend within
vaccine research to design delivery systems that are
able to mimic pathogens in size and composition.
Examples include virosomes, liposomes and polymeric
nanoparticles. Such structures may be loaded with
specific drugs of which they facilitate delivery to
intracellular compartments through pathways involved
in natural infections in order to obtain desired and
optimal immune responses against a given pathogen.
Although the field of immunology is outside the scope
of this text, a brief introduction is needed to get a better
understanding of the potential these carrier systems
have in vaccine antigen delivery.
After vaccination, or during natural infections,
antigen presenting cells (APCs) play a central and
orchestrating role for generation of adaptive immune
responses in mammals [6]. APCs include dendritic
cells (DCs), B-lymphocytes (B-cells) and macro-
phages, and their main role is to initiate an immune
response by alerting other cells about pathogens
entering the body. In fish, macrophages are consid-
ered to be the target orchestrator of adaptive immu-
nity. DC-like cells have only recently been identified
[51], and the role of B-cells as APCs is preliminary
described [49]. Macrophages have the ability to
phagocytose (engulf and digest) pathogens and
present the foreign antigens on the cell surface to
prime other cells to recognize the same structures.
Depending on the agonist (adjuvant/antigen), acti-
vation of macrophages initiates the humoral (antibody
production) and/or the cellular (cytotoxic T cells) arm
of the immune response. These two arms are effector
mechanisms against extra- and intracellular patho-
gens, respectively.
Most vaccines elicit a humoral response result-
ing in antibody production. As they seem to fail to
activate the cellular immune repertoire they pro-
vide poor protection against intracellular patho-
gens. The latter represents a key challenge in
antiviral vaccine design [77]. Cellular responses can
generally not be induced by non-living vaccines
[53]. While potentially effective, not least within
veterinary vaccines [18], the use of attenuated virus
strains includes the risk of virus reverting into
virulent forms (e.g. [67]). However, the APCs have
the ability to initiate the cellular arm in response to
inactivated antigens, a property called cross-
presentation. Vaccine researchers can exploit this
property by designing vaccines that mimic intracel-
lular pathogens.
Immunobioengineering Using Small Polymeric
Particles
The use of polymeric micro- and nanoparticles in
vaccine delivery systems represents a novel approach
in the context of aquaculture. Aiming at modulating
immune responses in specific and desired ways, this
approach may be called ‘immunobioengineering’ as it
combines knowledge in material sciences with immu-
nology [35]. Increased vaccine efficacy and reduced
severity of side effects may be achieved by targeting
specific immune cells and their intracellular (signal-
ling) pathways [17, 55]. A broad range of low-toxic
60 Nanoethics (2011) 5:57–71and biodegradable materials can be used to make
micro and nano sized vaccine antigen carriers, with
PLGAs (poly lactide-co-glycolic acids) being among
the most extensively explored polymers for targeted
drug delivery. Due to their different physical and
chemical properties one can modulate co-polymer
composition (e.g. lactic:glycolic ratio, surface charge
and molecular weight) and particle size in order to
alter particle-cell interactions, degradation kinetics
and antigen release. Control of the rate of cellular
uptake and antigen release profiles can be utilized to
design vaccines with prolonged and/or pulsative
antigen availability and/or presentation in intra- and
extracellular compartments. The control of degrada-
tion profiles may also enable development of other
vaccine delivery systems for fish, two highly relevant
examples being oral or intramuscular (plasmid DNA)
vaccines.
Expected Benefits of PLGA Particles in Fish Vaccine
Formulations
The overall objective of developing a novel particle
based vaccine concept for fish is the same as for the
development of any other vaccines: to prevent
outbreak and spread of diseases. There are currently
no treatments for viral diseases in aquaculture. Given
the prophylactic approach taken by the Norwegian
aquaculture industry, vaccination therefore represents
a key strategy to combat diseases. Reduced incidences
of disease outbreaks and reduced adverse side effects
have positive implications for fish welfare as well as
cost-efficiency in the industry. For some diseases, like
the earlier mentioned IPN, the mortality during an
outbreak can be as high as 90% at one farm site. The
economic setback of such serious outbreaks can
exceed a million USD, not least when reduced fish
growth and product quality is taken into account. The
pertinence of the issue of fish welfare is emphasized
by the recent law on animal welfare in Norway, which
entered into force at the beginning of 2010 [60]. In
addition, spread of diseases between farmed and
wild fish is possible as they live in the same
environment, indicating that efficient vaccines may
also contribute to the preservation of a healthy and
viable wild life.
On a technical level, the PLGA particle delivery
system comes with a range of advantages. First, the
particles serve to protect against premature drug
degradation, and they enable spatio-temporal control
of drug release. This makes it possible to prepare
vaccines with controlled biodistribution, depot (anti-
gen availability over time), cellular targeting and
intracellular routing [46]. Second, the particles are in
the same size range as bacteria and viruses, and they
are therefore readily taken up by APCs [68]. It has
been shown that cross-presentation may be enhanced
when antigens are attached to (sub-) micron sized
particles as compared to the use of soluble antigens
(e.g. [40]). Third, PLGA particles can also be loaded
with ‘danger signals’ in order to elicit stronger
responses directed to stimulate the cellular arm of
the immune system [16, 21, 69]. By co-encapsulating
antigens and danger signals the two components are
able to effectuate their actions simultaneously,
thereby mimicking pathogens in size and composi-
tion. It has been shown that co-encapsulation of
antigens and danger signals in PLGA particles
induces a strong antibody response as well as a
cellular response [69].
In a broader perspective, PLGA vaccines formula-
tions may render use of live or plasmid DNAvaccines
redundant. This could be the case if the PLGA
vaccines have higher efficacy towards intracellular
pathogens than conventional oil-adjuvanted vaccines.
If use of DNA and genetically modified vaccines is
avoided, this would eliminate biosafety risks associ-
ated with the use of such vaccine concepts [24].
In sum, incentives to search for new and improved
vaccine concepts are evident from multiple perspec-
tives, including those of animal welfare, fish farmers
and the sustainability of wild fish populations. The
strategy of using PLGA nanoparticles in vaccine
delivery comes with a number of technical advan-
tages, which, however, remains to be demonstrated in
the context of salmon vaccines.
Uncertainties Regarding Harmful Effects of PLGA
Based Salmon Vaccines
The goal of using nanocarriers in drug delivery is to
achieve optimal prophylactic or therapeutic effects
while minimizing drug hazards. Nevertheless, it has
been questioned whether the safety of drug carriers
themselves have been appropriately scrutinized [36].
Another aspect of nanomedicines that generally has
been devoted scarce attention is their possible
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will systematically explore uncertainties regarding
harmful effects of PLGA based salmon vaccines.
Mapping Locations of Salmon PLGA Vaccines
While the vaccinated animal constitutes the focal
point for uncertainties relating to the vaccine, the
production and use of the vaccine may have unin-
tended effects at other locations (Fig. 1 below). To
begin with, it is relevant to know where the vaccine
material enters the body of the salmon. It can be
absorbed through the gut (edible vaccines), over the
gills (immersion vaccines), or it can be deposited in
muscle tissue or the abdominal cavity (injected
vaccines), the latter being most relevant for the PLGA
formulations addressed here. Further, it is relevant to
know the biodistribution and pharmacokinetics/
dynamics of the particles post injection. However,
the vaccine material may also be excreted or leak
from the individual. The salmon itself may escape
from the salmon farm facility and into the surround-
ing aquatic environment. Vaccine materials may also
enter the aquatic environment by way of vaccine
spills or through decomposition of vaccine containing
salmon tissue (e.g. offal and dead fish).
In addition, vaccine residues may end up in the
s a l m o nm u s c l et i s s u ea n dm a yb ec o n s u m e db yh u m a n s
or animals (e.g. escaped salmon in the wild). Finally,
humansmayphysicallycomeincontactwiththevaccine
through research, production and administration. The
following presentation of uncertainties regarding this
fish vaccine will generally move from left towards right
in Fig. 1. We revisit each of these locations to present
available knowledge and to identify knowledge gaps.
We start with a presentation of the PLGA material and
its application in delivery of therapeutics, notably
micro- and nanoparticle vaccines. Then we proceed to
concrete matters of salmon vaccines in the fish and
beyond. Reflecting the availability of knowledge along
this trajectory, our presentation will become decreas-
ingly anchored in existing research and accordingly
become increasingly suggestive.
PLGA and its Use in Delivery of Therapeutics
Nanomedicines, including nanoparticle based vaccines,
mainly involve two components; a drug and a carrier
system [36]. We begin with some general experiences
with its use in medical applications before we turn to its
use in small particles for drug delivery.
PLGA has been approved by the US food and drug
administration (FDA) for a range of medical clinical
applications [50]. PLGA has for instance been used in
surgical sutures [26] and in bone fracture fixation in
humans and other mammals. Concerning their safety
Salmon farm system
Excretions?
Salmon individual 
Distribution?
Degradation?
Physiological effects? Vaccine spills?
Salmon escape?
Dead fish?
Offal?
Effects for human consumers?
Salmon product
Aquatic system 
 PLGA 
vaccine
Effects for 
researchers, 
producers and 
vaccinators?  
Fig. 1 Conceptual map locating conceivable uncertainties of
salmon vaccines in relation to a nested system of potential
containment or leakage. Once administrated, vaccines may be
contained within (or leaked from) an individual salmon. In turn,
the salmon may be contained within the salmon farm system or
may escape into the external aquatic environment. Slaughtered
salmon, which may contain vaccine, enters into a (terrestrial)
production chain, making it available for human consumption.
Professionals may come in contact with the vaccine through
research, production and administration of the vaccine (see text
for discussion)
62 Nanoethics (2011) 5:57–71in medical application and otherwise, PLGAs have
two general advantageous properties: Biocompatibil-
ity and biodegradation, properties often stated as part
of what motivates new applications.
The PLGA molecule degrades in an aqueous
environment, whether in vitro or in vivo, because
the ester bonds that form the backbone of the polymer
will hydrolyze, releasing the lactic acid and glycolic
acid of which it is constituted. These acids are
eventually metabolized though the citric acid cycle
or excreted [4]. The rate of degradation depends on a
range of factors such as co-polymer composition (i.e.
the ratio of lactic to glycolic acid), site of administra-
tion, additives (including drugs in delivery systems),
size, surface charge and shape of the device or
particle, and its porosity and pH [5, 9, 23, 32, 65,
76, 78].
The biocompatibility of PLGA has been reviewed
previously [2, 4]. In macroscopic applications, PLGA
has been found to be biocompatible over longer time
horizons (e.g. several months to more than a year) and
the documented side effects of PLGA appear limited
to that its degradation may cause acidic conditions
locally [4]. Small PLGA particles, however, have
been found to elicit inflammatory processes. It has
been suggested that the chemical- (co-polymer com-
position, molecular weight etc.) and physical proper-
ties (size, shape, surface charge) of the particle may
be responsible for the variations in the intensity and
duration of the inflammatory and wound healing
processes [2].
Important in vivo characteristics of PLGA nano-
and microparticles include their biodistribution,
pharmacokinetics/dynamics and cellular uptake. For
instance, one reason that nanoscaled (as opposed to
microscaled) particles have been found to be of
interest in drug delivery is that they can be trans-
ported (passively or actively) to tissues/cells distant
from the site of injection. This makes it possible to
design drug carrier systems that can pass biological
barriers and seek target tissues where the drug can
perform more efficiently.
We note that a recent expert review on clinical
applications of PLGA based nanotechnology stated
that a widespread clinical use of PLGA nanoparticles
in clinical trails should be preceded by a thorough
evaluation of their pharmacokinetics, biodistribution
and immunotoxicity [50].
PLGA Particles in Salmon Vaccines
When we shift from mammals (in particular non-
human primates and rodents) to fish, the lack of
studies on effects of PLGA particles is much more
obvious. Indeed, we have not encountered studies
dedicated to the examination of these issues regarding
use in fish. This is not unexpected since the use of
PLGA particles in vaccine delivery in fish is a rather
new research area, only addressed in a few publica-
tions [10, 45, 61, 72, 73]. These studies involve use of
different research animals and vaccine concepts as
summarized in Table 1.F i r s t ,t h ef i v es t u d i e s
comprise four different species. Second, the three
most recent studies aimed at developing vaccines
against diseases affecting Japanese flounder (Para-
lichthys olivaceus) and Indian major carp (Labeo
rohita)−species that are very different from salmonids
in terms of physiology and habitat (e.g. temperature
Table 1 A summary of selected characteristics from previously published studies on PLGA vaccines on fish. Note that these studies
were in the field of immunology
Study Species Particle size Administration
site
Polymer Antigen Negative side
effects
[61] Atlantic salmon
(Salmo salar)
~5 μm( 2 –
10 μm)
Oral delvivery PLGA 85:15 Human gamma
globulin (HGG)
None mentioned
[45] Rainbow trout
(Oncorhynchus mykiss)
~1 μm Oral delivery PLG HGG None mentioned
[73] Japanese flounder
(Paralichthys olivaceus)
<10 μm Oral delivery PLGA 75:25 pDNA No apparent
anaphylaxis
[72] Japanese flounder
(Paralichthys olivaceus)
<500 nm Oral delivery PLGA 75:25 pDNA None mentioned
[10] Indian major carp
(Labeo rohita)
~1 μm Intra-peritoneal
injection
PLGA 50:50 Aeromonas hydrophila
(bacterial antigens)
None observed
Nanoethics (2011) 5:57–71 63and behaviour). Finally, the studies involved use of
different drugs (antigen sources), polymer composi-
tion and particle sizes.
None of these studies report negative side effects.
However, as registration of adverse side effects did
not appear to be a major focus in these studies, no
conclusions can be drawn in this respect, except that
there seems to be a lack of targeted research on
adverse effects.
One of the authors (B. N. Fredriksen) participates
in an ongoing salmon PLGA vaccine project, in
which several sub-experiments have been performed,
including one on Atlantic cod (Gadus morhua). In
these experiments, model- and pathogen derived
antigens were encapsulated. Like the studies listed
in Table 1, these experiments were designed to
answer questions in immunology, not to address side
effects of vaccination. Although the experimental
setup did not involve systematic registration of side
effects, some trends were observed. In salmon, one
antigen-polymer combination resulted in quite
severe side effects. However, when the same
polymer was used to prepare particles for similar
experiments using a different antigen (also in
s a l m o n )i td i dn o tr e s u l ti na n yo b s e r v a b l es i d e
effects. In cod, using a different polymer and twice
the particle dose (due to low antigen loading in the
particles), severe side-effects like exophthalmia
(bulging eyes) and pigmentation were observed in
the nanoparticle injected group. Such side effects
were not seen in the oil-adjuvanted and non-injected
groups. Observations like these may indicate that the
combination of polymer and antigen is of importance
for the differences in reactogenicity and immunoge-
nicity between the formulations. Such antigen-
formulation related side effects have also been
observed for oil-adjuvanted vaccines [55].
PLGA Particles in the Aquatic System
Salmon farms are semi-open systems interconnected
with a surrounding aquatic environment. Although
efforts have been invested to minimize salmon
escapes, this remains a persistent problem. In combi-
nation with the biomass and numbers of vaccinated
animals, the semi-open character of salmon farms
presents us with a context in which the potential
environmental implications of vaccine use are partic-
ularly important to evaluate.
Since PLGA particles will be subjected to hydroly-
sis in an aquatic medium they will be degraded over
time if released into the environment from vaccine
spills or decomposing tissues. However, degradation
rates of the particles in the context of salmon farming
have not been described. Since salmon is farmed at
relatively low temperatures (generally between 5 and
15°C) in Norway, we may expect slow degradation
rates compared to experiments conducted in vitro at
37°C. A highly important issue concerns the extent to
which the nanoparticles can aggregate in the environ-
ment [66]. Aggregation may influence degradation
rates of particles and their potential to affect organisms
in the environment. It appears that little or no
information is available about this aspect of PLGA
nanoparticles in a marine context.
Accordingly, there is a need to initiate experiments
investigating the stability of PLGA particles in
aquatic systems, their uptake in aquatic organisms,
including marine fish and mammals. While PLGA in
itself seems to have a low potential for being toxic,
we should not rule out the possibility that more
complex structures of the polymer and combination
with other compounds could give rise to undesirable
properties. Since one of the major advantages of
PLGA particles is that they are versatile carriers
suitable for delivery of a wide range of therapeutics, it
may be speculated that they could act as “Trojan
horses” for different problematic substances in the
environment. Due to their ability to attach hydropho-
bic or hydrophilic compounds and their ability to
cross biological membranes, it is not entirely implau-
sible that such particles could serve as carriers in
unexpected and undesirable ways.
Occupational Health and Human Consumers
Although we know something about PLGA in
mammals, this does not provide us with primary
information about how humans may react to PLGA
nanoparticle based fish vaccines. Such information,
however, would be relevant for evaluating safety
concerns of vaccine researchers, producers, vaccina-
tors and salmon consumers.
The particles, which come in the form of a (freeze-
dried) powder, are easily transported in air (B.N.
Fredriksen, personal observation). In the literature we
didnotencounterstudiesonhealthimpactsbyinhalation
of PLGA particles. We note here, however, that particles
64 Nanoethics (2011) 5:57–71made of PLGA are biodegradable and are considered to
be generally biocompatible. Further, rather low rates of
PLGA uptake in human intestinal and bronchial cells
have been reported[12]. Yet we consider it important to
perform targeted research to identify adverse effects by
inhalation, and that precaution is taken through ordinary
means such as using face masks and fume hoods in
research and production settings.
After production, the next step will be vaccination of
fish. Here, the safety of workers needs attention. Self
injections of fish vaccines by fishvaccinators, have been
found to cause mild to more serious immunological
r e a c t i o n si nh u m a n s[ 48, 64]. Although vaccination of
fish is generally carried out by experienced professio-
nals self-injections are not uncommon. In a range of
interviews, 29 professional vaccinators reported ‘one to
more than 50 jabs or self injections’ ([48]: 384). The
significance of self injection is reflected in that a
Norwegian fish vaccination handbook dedicates this
concern a complete chapter [3]. Further, if a PLGA
particle based salmon vaccine is to be marketed, it may
be appropriate to monitor vaccinators for unexpected
inflammatory and immunotoxic effects.
As farmed salmon is supposed to end on the dinner
table, it is necessary to investigate whether the salmon
filet or product contains vaccine residues. Although
one can assume that the PLGA has been biodegraded
in the time span between vaccination and slaughter-
ing, this assumption needs to be followed up by
experiments. As we address below, however, exami-
nations and documentation of such issues form part of
the regulatory requirements for vaccines used in
animals for human food [28].
Regulatory Aspects
In the European Economic Area (EEA), advanced
regulatory regimes have been developed to ensure the
safety and efficacy of veterinary vaccines [28],
including vaccines for fish [1]. However, nanomate-
rials have not previously been encountered in the
regulatory context of fish vaccines, and it therefore
remains to be seen how challenges raised by nano-
medicines will be responded to here.
1
For a new veterinary medicine to acquire a
marketing authorization valid for the EEA, a range
of conditions must be fulfilled. The producer of a
veterinary medicine has the responsibility for provid-
ing documentation of (among other things) the
medicine’s therapeutic effect on the target organism
and of the risks of adverse effects for animals,
humans and the environment, respectively. In addi-
tion, a withdrawal period for animals intended for
human consumption is determined in respect to
established Maximum Residue Limits for pharmaco-
logically active substances.
2
The process of obtaining a market authorization for
a new fish vaccine is a rather demanding, time
consuming and costly affair, of which we cannot
provide an adequate review here [1, 47].
3 Because
Norway is a major player in salmon aquaculture and
fish vaccine research in Europe and worldwide, it is
relevant to consider a possible source of regulatory
uncertainty within the Norwegian fish medicine
regulations. In general, Norwegian regulations for
veterinary medicines are shared with the EEA. As
concerns fish medicines, the National Medicines
Agency may, when this is applied for by individual
veterinarians, allow the use of products before they
have been granted a Norwegian marketing authoriza-
tion [58]. Further, in the case of ‘serious epidemic
diseases’ for which ‘there exists no suitable medi-
cine’([34]: §2–7), the Agency, may even allow the use
of fish medicines that have not been approved in any
EEA country. In critical situations, hence, there is a
formal procedure in Norway allowing medicines to be
taken into use before they have been fully risk
assessed—a practise that historically has not been
unexceptional. The rationale of this exemption is of
course that the risk associated with developing
epidemics justifies taking more risks with regard to
side effects of vaccines.
Two factors count in favour of the existing
framework regulating and overseeing the use of
vaccines for fish, including prospective nanomedi-
cines. First, it requires substantial and direct testing of
efficacy and side effects of any new vaccine. Second,
1 This is in contrast to, for instance, the European Community’s
framework for regulating chemicals, for which questions about
how to regulate nanomaterials receives considerable attention
(see e.g. [14])
2 Apparently, however, no Maximum Residue Limit has been
determined for PLGA in foodstuff so far [19].
3 See: http://www.ema.europa.eu/ema/index.jsp?curl=pages/
regulation/landing/veterinary_medicines_regulatory.jsp&murl=-
menus/regulations/regulations.jsp&mid=WC0b01ac058001ff8a
(last visited 12.12.2010)
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cines. The question we raise is whether the particular
features of nanomedicines will be taken into account
in this framework in sufficiently robust way. Will
established risk assessment and monitoring proce-
dures be adequate for considering long-term side
effects in target animals, the environment, and human
consumers when it comes to nanomedicines?
Anticipating Nanovaccines for Salmon:
Assessment and Recommendations
We have examined expected benefits and potential
harms of the use of PLGA nanoparticles in vaccines
for farmed salmon. Given the complexity of the case,
we do not consider this work a complete assessment.
A more comprehensive assessment would in particu-
lar require a closer examination of regulatory aspects.
Here we will go over the main points from our
examination, which in turn will provide a basis for
our suggestions for how governance of such fish
vaccines in practice may be prepared for.
We have characterized the rationale and prospec-
tive benefits of using small PLGA particles in salmon
vaccines. Obvious benefits of improved salmon
vaccines include improved animal welfare and eco-
nomics of salmon farming. In addition, improved
vaccines may reduce the spread of infectious diseases
to wild salmon.
The main emphasis of this work has been on the
mapping of potential harmful effects, which we
structured in terms of their location (Fig. 1). For each
location addressed, we presented available knowledge
about possible negative side effects, and we identified
knowledge gaps. We began with a focus on the PLGA
material and its various therapeutic uses in mammals
(including humans), of which there is an extensive
scientific literature. We then considered the more
specific application of PLGA in fish vaccines, of
which few studies are currently published. From the
target area of the injected vaccines we shifted
outwards (in Fig. 1) to a consideration of potential
side effects for the fish, the aquatic environment,
professionals working with producing or administer-
ing the vaccine, and humans consuming vaccinated
fish and regulation issues. Moving out from the
vaccines target area, the available scientific informa-
tion increasingly got sparse and less specific, imply-
ing that, in the terminology of Walker et al. [74], the
level of uncertainty increased towards ignorance. A
similar pattern has been identified for other novel
types of fish vaccines [27]. As a corollary, our
considerations became increasingly suggestive as we
moved away from the vaccine’s target area.
The addressed PLGA vaccine concept comes with
two particular sources of uncertainty, which relate to
the use of particles in the nano range and to context
sensitivity regarding the exact PLGA particle based
vaccine formulation being used. We recognized the
importance of context sensitivity in different ways.
Importantly, the safety of the carrier depends on what
it carries and vice versa (interactive effects). For
instance, we noted this in relation to the observations
from ongoing experiments with PLGA particle based
vaccines for salmon and cod. Further, while informa-
tion about the use of PLGA particles in delivery of
therapeutics in mammals is abundant, the context of
fish vaccines raises the question of to what extent
knowledge about one group of animal species (e.g.
mammals) is relevant for another (e.g. fish). This
relevance may even be questioned regarding more
closely related species.
The lack of context specific information relevant
for the evaluation of environmental and health aspects
of a PLGA based salmon vaccine owes much to the
fact that such a vaccine has not yet been suggested as
a product; it remains in an explorative research phase
as we write, and much of the information presently
available is indirect insofar it stems from research
focusing on vaccine efficiency, not its safety aspects.
If such a vaccine concept would be perceived to be
sufficiently promising (i.e. high level of protection
and low level of negative side effects), its efficacy,
product quality and safety would need to be docu-
mented in accordance with existing regulations.
While this documentation process would generate
context specific information, a pivotal issue is
whether ‘nano aspects’ would be sufficiently taken
into account. This issue is addressed in our recom-
mendations, to which we now turn.
First, we recommend the prioritisation of research,
which is not only targeted to testing and improving
the efficacy of vaccines, but which contributes to a
thorough evaluation of effects in terms of pharmaco-
kinetics, biodistribution and immunotoxicity of small
PLGA particles following vaccine administration.
Further, there is a need of research into methods to
66 Nanoethics (2011) 5:57–71measure such effects, not only in salmon, but also in
humans, animals and the environment. This includes
research investigating the stability of PLGA particles
in aquatic systems, and their uptake in aquatic
organisms. For instance, tests of intestinal contents
of predators and of microbial flora in the immediate
environment of vaccinated subjects may provide
indications of the environmental release and persis-
tence of PLGA particles.
Second, while PLGA in itself seems to have a low
potential for being toxic, we noted that it could have
unanticipated outcomes such as PLGA particles
serving as ‘Trojan horses’ for problematic substances
in the environment. Accordingly, the potential role of
the PLGA particles to act as carriers of toxic
compounds should be examined, as should their
potential for having harmful synergistic effects with
other particles and chemicals.
Third, as we moved outwards from the vaccine’s
target areas in Fig. 1, knowledge of effects became
scarce, and we moved into ignorance. In situations
characterized by ignorance, it is important to initiate
research into methods for detection and monitoring of
unanticipated effects. While there exists an interna-
tionally coordinated system for reporting ‘suspected
adverse events’ for veterinary medicinal products
authorised in the EEA,
4 methods should preferably
be developed for detecting persistence and biodistri-
bution of small (e.g. sub micron) particles. As
suggested by Wickson et al. [75] monitoring of
unanticipated effects is not only a task for scientists,
but would here naturally involve manufactures of the
vaccines, vaccinators, veterinarians, and fish farmers.
Finally, we recommend that present scientific
knowledge, and its limitations, should be exposed to
some form of extended peer review [25] prior to that
nanoparticle based salmon vaccines are taken into use
on a larger scale. The framework suggested by Walker
et al. [74], perhaps as simplified and adapted here,
may be useful for enabling a structured presentation
of available scientific knowledge and uncertainties in
relevant areas. Such a presentation could provide a
background for an extended review process, which
preferably should involve participants of complement-
ing scientific disciplines, regulators, organized inter-
est groups and members of a broader public (e.g.
consumers). Questions that may be relevant to address
here include: Is the size reduction from PLGA
microparticles to PLGA nanoparticles critical with
regard to risks in this new context? May fish respond
in different ways than humans or other mammals,
about which we have previous information regarding
the biocompatibility of PLGA? Does the large-scale
use of PLGA in semi-open systems such as salmon
aquaculture facilities represent different, e.g. environ-
mental, risks than its previous uses?
Anticipatory Governance of Nanotechnologies—
The Challenge of Nano-Diversity
There is a strong motivation to anticipate unwanted
effects of technologies as early as possible. In general,
this motivation stems from previous experiences with
novel technologies that turned out to have unexpected
and harmful effects [31]. Technology researchers and
developers have a particularly compelling incentive
for seeking to anticipate harmful effects, which
derives from the fact that product development (i.e.
testing and documenting efficacy, quality and safety)
is lengthy and costly. There is simply no point in
testing a concept (e.g. a vaccine) before one is
reasonably sure that it will be good and safe. If
modified, however slightly, the concept would require a
new round of tests and documentation. This incentive
can be utilized in the facilitation of anticipatory
governance approaches, whether through interdisciplin-
ary exercises or through other approaches that we return
to below.
A well known challenge for any evaluation of a
technology at an early stage is that little knowledge will
be available for supporting the evaluation [15]. In the
present case, it proved difficult to evaluate potential
harmful effects of a vaccine concept, which is not yet
stabilized in the sense that different vaccine/particle
configurations are still being tested. In general, little
context specific information will be available (i.e.
published) prior to that a technology has been tested
and documented regarding its efficacy and safety. In
this situation we believe that researchers exploring the
technological concept in question will represent the
most valuable source of context specific knowledge
about safety, side effects and knowledge gaps.
We believe that efforts to anticipate harmful effects
of nanotechnologies will meet a further challenge.
4 http://eudravigilance.emea.europa.eu/veterinary/(last visited
14.12.2010)
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be extremely difficult for any singly agency to
maintain an overview of nanotechnology research as
such. In particular, it is difficult to overview the
diverse array of individual research projects that are
carried out by research groups located in environ-
ments that (such as it is the case for the discussed fish
vaccine project) are not defined, organized or identi-
fied as nanotechnology research environments as such
(see Nielsen et al. [57], this issue). Low profile
nanotechnology projects of different kinds may not
receive much attention from research environments
dedicated to the evaluation of the toxicology and eco-
toxicology of nanomaterials. We suggest that tech-
nology researchers also represent an invaluable
resource for addressing this challenge.
The approach taken here represents one way to
utilize tacit and explicit knowledge of technology
researchers in order to facilitate anticipatory gover-
nance in a given context. We found that the
interdisciplinary aspect of our approach allowed for
useful synergies when characterizing benefits, risks
and uncertainties as well as issues in need of further
research at an early stage of technology development.
However, it appears unlikely that there will be time
and resources available for conducting exercises of
this kind in relation to all nanotechnology projects.
Accordingly we end this article by endorsing the
further development of voluntary measures and codes
of conducts for good technology research practises,
which we see as complementary ways to mobilize the
knowledge of technology researchers in anticipatory
governance efforts.
Approaches that seek to promote a broad sense of
responsibility [38] among technology researchers may
help to anticipate unwanted side effects. For instance,
voluntary instruments such as the EU’s “Code of
Conduct for Responsible Nanosciences and Nano-
technologies Research” [13] may help in rendering
researchers more sensitive to potential environmental
health and safety implications of their research. In
Norway, a more general set of “Guidelines for
Research Ethics in Science and Technology” [56]
has been suggested, which among other things seeks
to make precautionary thinking relevant for individual
researchers in upstream settings [71].
Soft law approaches, however, are not unproblem-
atic. We observe that there apparently, at least in a
Norwegian nanotechnology research setting, is little
awareness of both the EUs Code of Conduct and the
Norwegian guidelines for research ethics.
5 Further,
we note that these guidelines in themselves are
problematic. In particular, the present Norwegian
guideline confers the individual researcher with
quite demanding obligations, and it appears unclear
how s/he may fulfil a responsibility in the way it
is outlined. There seems to be challenges with, as
well as a scope for improvement of, approaches
that involve technology researchers in anticipatory
governance efforts.
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